CRNX
Crinetics Pharmaceuticals, Inc. · Healthcare
Insiders sold $366K net in the last 90 days ·2 sellers, 0 buyers· 2 of 2 sales under Rule 10b5-1 plans· latest Form 4 filed Jul 7, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.5M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Sep 1, 2026
Vivaldi Coelho Rogerio
Crinetics Pharmaceuticals, Inc. (CRNX) has 40 SEC Form 4 filings (90 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Sep 1, 2026.
Inside the rolling window, 8 insiders at Crinetics Pharmaceuticals, Inc. reported no open-market purchases and 12 open-market sales totaling $6.5M. Insiders have net sold $5.6M over the trailing 6 months. The most recent open-market filing is a sale of 3,000 shares by Director Vivaldi Coelho Rogerio, dated Jul 2, 2026, worth $120K.
- Industry:Biotechnology
- CEO:R. Scott Struthers
- Employees:594
- HQ:San Diego, CA, US
- IPO:2018-07-18
| Source | |||||||
|---|---|---|---|---|---|---|---|
Vivaldi Coelho RogerioFirst in 4 months | Director | Sale | 3,000 | $120K | Jul 7 | +1.7% | SEC ↗ |
Okey StephanieFirst in 3 months | Director | Sale | 6,900 | $246K | Jun 18 | +136.8% | SEC ↗ |
| Chief Dev. & Operating Officer | Sale | 85,163 | $3.4M | Apr 10 | +115.4% | SEC ↗ | |
Struthers Richard ScottFirst filing | President & CEO | Sale | 21,981 | $822K | Mar 18 | +135.6% | SEC ↗ |
Knight Jeff E.First filing | Chief Operating Officer | Sale | 9,911 | $370K | Mar 18 | +135.6% | SEC ↗ |
Betz Stephen F.First filing | Chief Scientific Officer | Sale | 10,612 | $397K | Mar 18 | +135.6% | SEC ↗ |
Vivaldi Coelho RogerioFirst filing | Director | Sale | 5,000 | $181K | Mar 13 | — | SEC ↗ |
Okey StephanieFirst filing | Director | Sale | 3,000 | $119K | Mar 4 | — | SEC ↗ |
Schilke TobinFirst filing | Chief Financial Officer | Sale | 6,713 | $266K | Mar 4 | — | SEC ↗ |
Kalofonos IsabelFirst filing | Chief Commercial Officer | Sale | 2,500 | $138K | Jan 7 | — | SEC ↗ |
| Chief Med and Dev Officer | Sale | 5,000 | $225K | Dec 3 | — | SEC ↗ | |
Pizzuti DanaFirst filing | Chief Med and Dev Officer | Sale | 5,000 | $213K | Nov 5 | — | SEC ↗ |
Congress trading CRNX 3 all-time
- DRep. Gilbert CisnerosSale$15,001 - $50,0002026-07-30
- DRep. Gilbert Ray CisnerosOther$15,001 - $50,0002026-07-29
- DRep. Josh S. GottheimerPurchase$1,001 - $15,0002024-09-25
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does CRNX have?
Crinetics Pharmaceuticals, Inc. (CRNX) has 40 SEC Form 4 filings (90 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Sep 1, 2026.
When was the most recent SEC Form 4 filing for CRNX?
The most recent Form 4 filing for CRNX on Tracefour is dated Sep 1, 2026.
What is the net insider flow at CRNX over the last 6 months?
Over the trailing 180 days, insiders at CRNX have net sold $5.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at CRNX in the current window?
Inside the rolling window, insiders at CRNX bought $0 and sold $6.5M based on SEC Form 4 filings.
Can I get alerts for CRNX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Crinetics Pharmaceuticals, Inc. (CRNX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Crinetics Pharmaceuticals, Inc. is in the Healthcare sector.